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INTRODUCTION 
According to the World Health Organization (WHO), obesity is the most 
common public health problem in both developed and developing countries (1). 
According to the World Health Statistics Report 2012, one among six adults is 
obese and approximately 2.8 million individuals die every year due to overweight 
or obesity (2), now obesity is being recognized as a disease because of its increased 
risk of morbidity and mortality . In India the prevalence of obesity (generalized 
and abdominal) is higher with females which include 20 million obese women in 
2014 compared to 9.8 million obese men (3).  
 
Obesity is strongly associated with diabetes mellitus, gall bladder disease, 
certain cancers (endometrial, breast, prostate and colon), cardiovascular diseases 
(such as stroke and coronary heart disease) and non-fatal diseases including gout, 
respiratory conditions, gastro-esophageal reflux disease, osteoarthritis and 
infertility. A high level of Low Density Lipid (LDL) is also a risk factor for 
Coronary Heart Disease (4). Due to an evolving societal prejudice against fatness 
obesity induces serious implications for psychosocial health. The risk for this 
disorder depends on the body mass index (BMI) of about 21kg/m2 (5). 
 
Several reports suggested that obesity is associated with the 
polymorphisms in genes controlling appetite and metabolism. Development of 
obesity is linked with the variation in such genes which are more than 41 in 
number (6). In man lipoprotein complexes with one or more apolipoproteins are 
transported in blood which are derived from insoluble lipids.  Low-density 
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lipoprotein (LDL) is comprises of 75% lipid (cholesterol and cholesteryl esters) 
and 25% protein (7).  ApolipoproteinB (ApoB) the main protein component of 
Very Low Density Lipid (VLDL) and LDL acts as a key role in lipid metabolis in 
addition for removal of LDL from the circulation by LDL-receptor-mediated 
endocytosis it serves as the ligand (8). The primary responsibility for transporting 
cholesterol in LDL to tissues, the protein ApoB plays the major role. ApoB on the 
LDL particle acts as a ligand for LDL receptors in various cells throughout the 
body. Atherosclerosis is caused by high plasma ApoB levels [9]. Variation in the 
apoB gene is involved in the pathogenesis of obesity. The gene encoding for 
human ApoB [ID: 338] is of 43 kb in length, located exactly on the short arm of 
Chromosome 2 (2p23-p24) [10].  
 
Several single nucleotide polymorphisms in the apoB gene particularly of 
Xbal, EcoRI and MspI have been closely associated with variation in lipid levels 
and obesity (11). This polymorphism is found to be associated with generalized 
obesity and increases the levels of various lipoprotein subfractions like 
triglycerides (TGL), total cholesterol (TC) and low density lipoprotein cholesterol 
(LDL-C). 
 
Epidemiological studies have revealed an association between apoB gene 
polymorphisms and obesity and an increase in various lipoprotein subfractions 
(total cholesterol [TC], low density lipoprotein cholesterol [LDL-C], triglyceride 
[TG]) and atherosclerosis.  
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It has been reported that the for the development of cholelithiasis 
(gallstones) in patients, X+ allele of the Apo B gene is a risk factor. Some of the 
study explains that there is no association between the obesity and apoB XbaI 
polymorphism (12). In this study we have attempted to correlate apoB XbaI gene 
polymorphisms in obese and non-obese patient with suspected coronary heart 
diseases.  
 
This study has been done in Kancheepuram district covering the area of 
120 villages near the 500 bedded tertiary care centre.  
 
Aims & Objectives 
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AIMS AND OBJECTIVES 
 
 The study aims to determine the detection and comparison of LDL receptor 
gene –Apo B polymorphism in obese and non – obese patients with suspected 
coronary heart disease. 
 
1. To determine the correlation between glucose levels  in obese and non 
obese patients with suspected coronary heart disease. 
2. To   determine   the   correlation   between lipid profile in obese and non 
obese with suspected coronary heart disease patients . 
3. To determine the Thyroid profile in obese and non obese with suspected 
coronary heart disease patients. 
4. To identify the LDL receptor Apo B polymorphism gene in obese and non 
obese with suspected coronary heart disease patients by Molecular 
Technique Polymerase Chain Reaction. 
Review of Literature 
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REVIEW OF LITERATURE 
 
Worldwide obesity has risen to higher proportions and has become a major 
worldwide health problem13. The highest rise in obesity levels among women has 
been found over the past three decades. 
  
People who are overweight have an increased risk of cardiovascular 
disease, cancer, diabetes, osteoarthritis, and chronic kidney disease, with most 
deaths due to cardiovascular problems, including heart attack and stroke. The 
obese patients have a history of diabetes mellitus, genetic predisposition for 
diabetes and coronary heart disease in family etc.  
 
The obese state has long been recognized to accentuate the common risk 
factors for atherosclerotic disease-hyperlipidemia, hypertension, and glucose 
intolerance. Evidence has also been presented that even after correction of obesity 
to be an "independent" risk factor for atherosclerotic disease by its association 
with risk factors. 
 
The associated risk factors along with obesity are high blood pressure, 
cigarette smoking, cholesterol (TC), LDL-C, HDL-C, and diabetes.  Patients with 
obesity, left ventricular hypertrophy, and family history of premature coronary 
heart disease have also considered in defining risk. 
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Family history of risk factors such as coronary heart disease, physical 
activity, and obesity are included because these factors and diseases, lifestyle and 
obesity are helpful to co-relate the coronary heart disease prediction. 
 
Usually elevated blood pressure are associated with abnormal cholesterol 
values, increased body in mass index, diabetes etc. High levels of body mass 
index, the more prevalence of diabetes mellitus, Triglyceride, LDL – cholesterol, 
high density lipoprotein cholesterol and blood pressure are the main cause of 
CVD. These are the preventive and intervention risk factors14. 
 
 Persons who exercise typically have a lower risk of CHD15 information on 
physical activity was not available at the baseline examinations used to develop 
this CHD risk prediction algorithm, but cigarette smoking, low HDL-C levels, and 
diabetes are less common among those who are physically active16- 19. Regular 
and vigorous exercise is often associated with higher levels of HDL-C, an 
important determinant for reduced CHD risk20- 22. 
 
 Similarly, “body mass index, an obesity index that expresses weight in 
kilograms divided by height in meters squared, has been considered a candidate 
variable for the CHD prediction algorithm. Greater obesity has been associated 
with higher TC, lower HDL-C, higher blood pressure, and diabetes, and the 
residual impact of obesity on CHD has typically been slight after incorporation of 
these other variables into the regression model23”. 
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It is uncommon for persons to have four or five hour risk factors, and 
estimates of CHD risk tend to be more precise for individuals with fewer risk 
factors. The average CHD rates reported in those tables are roughly comparable to 
the myocardial infarction and coronary death rates among middle-aged men who 
participated in the west of Scotland trail of cholesterol lowering24, 25.  
 
Past 10 years the risk for coronoary heart disease have a range of age, 
myocardial infarction and chest pain. 
 
A study that considered CHD prediction using TC, LDL-C, TC/HDL-C 
ratio, and LDL-C/HDL ratio26. The lipid profile and lipoprotein abnormalities 
have also been reported to be associated with measures of central obesity, such as 
waist-to-hip ratio in adults.   
 
Concluded that “total cholesterol / HDL is a superior measure of risk for 
CHD compared with either total cholesterol or LDL cholesterol, and that current 
practice guidelines could be high risk factor was based on this ratio other then the 
LDL – Cholesterol level.” 
 
 The acceleration of atherosclerosis is due to factor of obesity risk that 
obese subjects have abnormalities in lipoprotein metabolism. For example, “obese 
subjects without hyperlipidemia have been reported to have increases in synthesis 
of very low density lipoprotein (VLDL)-triglycerides (TG), VLDL-apolipoprotein 
B (apo B) (VLDL-B)27, 28, low density lipoprotein (LDL)-apo B (LDL-B)29, and 
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total body cholesterol30”. The abnormalities in VLDL, the precursor of LDL will 
enhance the rate of atherogenesis. 
 
 Researchers reported that body composition and thyroid hormones appear 
to be associated since thyroid hormones are involved in the basal metabolism and 
thermo genesis. The body metabolism is depends on lipid levels, glucose levels 
and metabolism, food intake and fat oxidation. 
 
 Hypothyroidism, the low levels of thyroid hormones causes increased 
weight and decrease the basal metabolism and thermo genesis. “There is an 
inverse correlation between free thyroxin (FT4) values and body mass index 
(BMI), even when FT4 values remain in the normal range. 
 
Always abnormalities in thyroid function may be secondary to weight 
excess”31. In various studies revealed that adult obese patients, thyroid hormone 
and thyroid stimulating hormone (TSH) concentrations have been described as 
normal, elevated or reduced. The high conversion rate of T4 been described as 
normal, elevated or reduced. 
 
The high conversion rate of T4 to T3 in obese patients has been also 
interpreted as a defense mechanism; capable of counteracting the accumulation of 
fat is increasing the energy expenditure, based metabolic rate32. 
 
Abnormalities in lipid levels and thyroid hormone in obesity patients 
increases the risk of cardiovascular disease regular monitoring of total cholesterol 
and thyroid hormone levels are mandatory in obese patients33. 
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 Obese related glomerulopathies are recognized complication of obesity. 
Renal biopsies and autopsy studies have reported that focal and segmental 
glomerulosclerosis (FSG) is the commonest histologic lession in obesity patients 
with symptoms of proteinuria34. 
 
Many experimental studies also showed the dyslipidaemia has major 
contribution renal injury, due to proliteration of mesangial cells and their 
extracellular discuss matrix induced by LDL cholesterol. The experimental study 
on zucker rat with obesity, researchers demonstrated hyperinsulinemia, 
hyperlipidaemia that leads to glomerulosclerosis and progressive renal failure35. 
 
The present study also included the factor of renal failure as a risk factor 
associated with lipid abnormality and ApoB gene polymorphism. Obese patients 
with hypertension are invariably associated with renal involvement become these 
abnormalities are interrelated pathogenically. 
 
 Obesity is characterized by inflammation with systemic involvement. 
Adipose tissue in obesity can be characterized by macrophage infiltration and 
associated inflammation in turn has been associated with anemia of chronic 
disease.  
 
This study reported and hypothesized that, “obesity may be associated with 
the features of anemia of chronic disease, including low hemoglobin. 
Concentration low serum iron and transferring saturation (TS) and elevated serum 
ferritin”. 
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Overweight and obesity were associated with changes in serum iron, TS, 
and ferritin that would be expected to occur in the setting of chronic, systemic 
inflammation. However, overweight and obese persons were not more likely to be 
anemic compared with normal-weight persons. 
 
 “A recently discovered 25-amino acid peptide called hepcidin is thought to 
be a key mediator of anemia of inflammation36- 37. Hepcidin is synthesized and 
secreted mainly by the liver and is detectable in blood and urine.  
 
Hepcidin is induced by elevated iron stores or inflammation and functions 
as a signal inhibiting intestinal iron absorption and sequestering iron in 
macrophages. A recent study reported that hepcidin is synthesized not only by the 
liver, but also by adipose tissue, and that hepcidin messenger RNA expression 
was increased in adipose tissue of obese patients38”. 
 
Compared to normal-weight persons, those in higher BMI categories were 
progressively less likely to have low serum ferritin. In contrast, persons with 
moderate or severe obesity were more likely to have low serum iron or TS.  
 
However, compared to normal-weight persons, all other higher BMI 
categories were not more likely to be anemic. As shown in previous studies, 
increasing BMI category was very strongly associated with elevated CRP, 
consistent with the presence of low-grade inflammation39. 
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Obesity:  
Obesity is one of the most common health problems in industrial societies 
(Grundy and Barnet 1990). Obesity is a health threat in part because it is 
associated with many other disease, including type II diabetes, gallstones and 
certain cancers (Grundy and Barnet 1990)39 with excessive mortality (NIH 
1985)40.  
 
Data from National Health Nutrition Examination Surveys (NHANES) 
show a high correlation between obesity and risk for coronary artery disease (NIH 
1985). It has also been shown that most obese people experience 
hypertriglyceridemia and hypercholesterolemia (Grundy and Barnet 1990).  
 
In addition, obesity is a very strong risk factor for hypertension. Obesity is 
epidemic in the United States (US) [Wilding 1998]41 and its prevalence is 
increasing (Grundy and Barnet 1990).  
 
Currently, the criteria for inclusion into the overweight and obese 
categories are a relationship of height and weight (Bray 1992b)42. Body mass 
index (BMI) is body weight in kilograms divided by height in meters squared. In 
adults aged 19 – 34 years, BMI of 19 – 25kg/m2 is considered normal, 25 – 30 
kg/m2 is overwight, >30 kg/m2 represents obese.  
 
In the US population of adults aged 25 years or more, 42% of men and 
28% of women are overweight and 21% of men and 27% of women are obese 
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(Must et al.1999)43. In 1991, the prevalence of obesity was 12.0% (Mokdad et al. 
1999)44 and increased to 17.9% in 1998.  
 
The incidence of obesity in every state, in both sexes and in all age groups, 
races and educational levels was increased. Nearly 10% of total health care costs 
are related to obesity (Wilding 1998)41. 
 
We often blame excessive eating and insufficient exercise for obesity; 
however there is still no concrete explanation for the fact that some people 
become obese, despite attempts not to, and others, apparently without much effort, 
do not (Ravussin and Danforth 1999)45.  
 
Genetic contributions to the development and maintenance of obesity 
cannot be eliminated. Studies in twins demonstrated an inherited tendency to gain 
weight in response to overfeeding (wilding 1998). Additionally, it was recently 
shown that there is unaccounted for physical activity in some people that prevents 
weight gain (Levine et al. 1999).  
 
Symptoms and complication associated with obesity: 
In obese person may have the symptoms of the medical condition 
mentioned below  
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They are include: 
 Breathing disorders includes  sleep apnea, chronic obstructive 
pulmonary disease)  
 Types of cancers (e.g., prostate and bowel cancer in men, breast and 
uterine cancer in women) 
 CHD 
 Depression 
 Hyper tension and type 2diabetes  
 Liver disease 
 High blood pressure 
 Increased  cholesterol content  
 Stroke   
 Psychological problems  
 
1. The concept of BMI 
 Quatelet in 1869 was the first person to observe that among adults of 
normal build but different heights, weight was roughly proportional to height 
square. Quatelet Index (Weight in kg. /Height in meters2) was later renamed 
‘body mass index (BMI)’ by Keys et al. (1972)46.  
 
BMI, Fat patterning and Mortality 
Waist circumference and waist – to- hip ratio, as opposed to BMI may be 
more specific indicators of total body fat and may therefore provided an improved 
means of determining the risk of mortality associated with obesity, especially in 
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the elderly. Many reports have shown that abdominal or central obesity is equally 
important as total adiposity and may be a better indicator of CVD risk46.  
 
Waist circumference, used as a surrogate of abdominal obesity, is highly 
correlated with visceral adipose tissue (Lemieux S, et al., 1996)47 and has been 
strongly linked with components of the metabolic syndrome, including glucose 
intolerance, hypertension, dyslipidemia and insulin resistance (Zhu S et al., 
2002)48. 
 
Few studies have evaluated the usefulness of waist circumference or waist 
– to – hip ratio, compared to BMI, when predicting mortality and those that have 
been inconsistent (Baik I, et al., 2000; Kalmijn S. et al., 1999; Price GM et 
al.,2006; Visscher TL. Et al., 2001)49- 51.    
 
The data from the Rotterdam Study (Visscher et al. 2001) of 6, 296 men 
and women from The Netherlands was used to study the relation of BMI, waist 
circumference and waist- to – hip ratio as predictors of all – cause mortality.  
 
Although this study had several methodological limitations, it showed that 
waist circumference and not BMI may prove useful for the prediction of all-cause 
mortality in the elderly. 
 
Waist-to-hip ratio however was significantly positively related to all – 
cause and CVD mortality among nonsmoking men and women. Waist 
circumference was not associated with mortality from all – causes or CVD among 
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men or women. The investigators were able to control for a wide range of 
potential confounders and effect modifiers. “healthy”. 
 
 This study provides powerful evidence that BMI may not be indicative of 
increased adiposity and mortality in the elderly and waist- to- hip ratio may add 
clinical utility when recommending a healthy body size in older adults. 
 
2.  Obesity Models 
There are many types of genetic mutations that result in pathophysiological 
signaling and metabolic alterations and which cause obesity in rodents (Guerre - 
Millo 1997). Two such models are the obese (ob/ ob) and diabetes (db/db) mice, 
both of which exhibit hyperphagia, profound early- onset obesity, hyperglycemia, 
hyperinsulinemia, infertility Colleman 1973), and defective thermoregulation 
(Coleman 1978)52 indicative of a hypothalamic defect.  
 
The phenotypes of the ob/ ob and db /db mice are identical and the strains 
can only be distinguished by genetic mapping or through parabiosis studies 
(Coleman 1973; Co1eman 1978)52. The results of parabiosis experiments suggest 
that there are satiety centers in the ob/ob and normal mice that respond to a 
circulation factor that is produced by db/db mice.  
 
The fa/fa genetic defect in rats was first discovered in the laboratory of 
Zucker and Zucker in 1961 as an autosomal recessive mutation mapped to 
chromosome 5 (Truett et al. 1991)53. 
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The Koletsky strain of rat develops obesity, hyperinsulinemia, 
hypertension, and proteinuria (Koletsky et al.1973)54 due to a single recessive 
gene with a mutation in the extracellular domain of the leptin receptor (Takaya et 
al.1996)55.  
 
3. Theories of Food Intake 
Several theories have been proposed to describe the mechanism of initiation of 
food consumption. Most of the theories revolve around the dual center hypothesis 
(Anand and Brobeck, 1951)56.  
 
The dual center hypothesis suggested that the lateral region of the 
hypothalamus, the “feeding center”, played a role in the initiation of feeding and 
the ventromedial region, the “satiety center”, inhibited feeding.  
 
 The amino static theory of food intake (Rogers and Leung, 1973) suggests 
that rats eat less when fed a diet devoid of certain amino acids, a diet with an 
amino acid imbalance, or a diet high in protein.  
 
The glucostatic theory (Mayer, 1953)57 suggest that there are glucose-
sensitive receptors, glucoreceptors, in the lateral hypothalamus that initiate 
feeding when blood glucose is low.  
 
3.1  Physical activity  
In sedentary live and less physical activity persons obesity is common. 
Obesity is common in the middle aged people though it can occur in all age group 
who have less physical activity and consume more calories. 
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3.2  Endocrine factor  
         Cushing’s disease, hypothyroidism and hypogonadism are the hormone 
factors for obesity. 
 
3.3  Trauma  
Damage of hypothalamus in head injuries will alter satiety and regular 
appetite functions that cause obesity. 
 
3.4  Prosperity and civilisation  
Obesity is common in prosperous countries like UK, USA, and in people of 
the higher economic strata of society, in developing countries. 
 
4.     Statistical analysis of overweight and obese people in India:  
WHO recently stated that the growth in the number of severely overweight 
adults are expected to be double than that of under-weight during 1995-2005 
(WHO 1998). Globalization is also playing an important role for modernization 
and sedentary life. So in near future obesity would emerge as a challenging 
problem for India.  
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Table 1.1 lists the states of India ranked in order of percentage of people who 
are overweight or obese. 
States Males ( %) 
Males 
Rank 
Females 
(%) 
Female 
Rank 
India 12.1 14 16 15 
Punjab 30.3 1 37.5 1 
Kerala 24.3 2 34 3 
Goa 20.8 3 27 3 
Tamil Nadu 19.8 4 24.4 4 
Andhra Pradesh 17.6 5 22.7 10 
Sikkim 17.3 6 21 8 
Mizoram 16.9 7 20.3 17 
Himachal Pradesh 16 8 19.5 12 
Maharashtra 15.9 9 18.1 13 
Gujarat 15.4 10 17.7 7 
Haryana 14.4 11 17.6 6 
Karnataka 14 12 17.3 9 
Manipur 13.4 13 17.1 11 
Uttarakhand 11.4 15 14.8 14 
Arunachal Pradesh 10.6 16 12.5 19 
Uttar Pradesh 9.9 17 12 18 
Jammu and Kashmir 8.7 18 11.1 5 
Bihar 8.5 19 10.5 27 
Nagaland 8.4 20 10.2 22 
Rajasthan 8.4 20 9 20 
Meghalaya 8.2 22 8.9 26 
Odisha 6.9 23 8.6 25 
Assam 6.7 24 7.8 21 
Chhattisgarh 6.5 25 7.6 27 
West Bengal 6.1 26 7.1 16 
Madhya Pradesh 5.4 27 6.7 23 
Jharkhand 5.3 28 5.9 28 
Tripura 5.2 29 5.3 24 
Delhi 45.5 36 49.8 64 
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 5.  Obesity and CVD: 
Obesity and overweight increase the risk of several serious chronic 
diseases, such as type 2 diabetes, cardiovascular disease, hypertension and stroke, 
hypercholesterolemia, hypertriglyceridemia, arthritis, asthma and certain forms of 
cancer and weight gain is associated with a high risk of developing cardiovascular 
and metabolic diseases such as coronary heart disease, hypertension, diabetes and 
dyslipidemia.  
 
Epidemiological studies have documented a close relationship between 
body mass index and cardiovascular events (Berchtold P et al., 1981)58 
 
The association of increased body weight (Obesity) with elevated levels of 
triglycerides and diminished HDL cholesterol has been described in both adults 
and children.  
 
Persons who exercise typically have a lower risk of CHD.  Risk of CHD 
and diabetes are less common among those who are physically active. Regular 
and vigorous exercise is often associated with higher levels of HDL-C, an 
important determinant for reducing the risk of Coronary Heart Disease.   
 
Similarly, “body mass index, an obesity index that expresses weight in 
kilograms divided by height in meters squared, has been considered a candidate 
variable for the CHD prediction algorithm. Obesity is appreciated with 
Triglycerides levels, elevated blood pressure and diabetes mellitus. The obesity on 
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coronary heart disease of these variables associated with regression model (Berns 
et al., 1989)59.  
 
Persons with less CHD risk factors is not possible to compare the persons 
with 2 or 3 risk factors. The score sheet used in the target persons for the 
prevention of CHD. It is used by a tabular form called Sheffield tabular column.  
 
It is used to estimate risk of coronary heart disease. It is a threshold for risk 
interventions. The average CHD rates reported in those tables are roughly 
comparable to the prevalence of myocardial infarction and coronary death rates 
among middle-aged men who participated in a trial study done at the west of 
Scotland.  
 
Kinosian B ET AL., 1955, they concluded that while predicting CHD using 
TC, LDL-C, TC/HDL-C ratio and LDL-C/HDL ratio, the total cholesterol / HDL 
is a superior measure of risk for CHD when compared with either total cholesterol 
or LDL cholesterol, and the guidelines for the current practice could be more 
efficient if risk stratification was based on this ratio (Albrink MJ et al., 1981)60. 
 
 The lipid profile and lipoprotein abnormalities have also been reported to 
be associated with measures of central obesity, such as waist-to-hip ratio in adults. 
 
The acceleration of atherosclerosis is due to the risk of obesity since those 
subjects have abnormalities in lipoprotein metabolism. For example, obese 
subjects without hyperlipidemia have been reported to have increased synthesis of 
very low density lipoprotein (VLDL)-triglycerides (TG), VLDL-apolipoprotein B 
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(apo B) (VLDL-B), low density lipoprotein (LDL)-apo B (LDL-B) and total body 
cholesterol.  
 
Several studies showed that these abnormalities in VLDL, the precursor of 
LDL will enhance the rate of atherogenesis (Ostlund RE et al., 1900; Streja et al., 
1980)61, 62. 
 
Alternatively there is significant weight loss has been shown to result in 
decreased triglyceride and increased HDL cholesterol concentrations. 
 
      Cardiovascular disease (CVD) is the leading cause of death and disability in 
developed nations and is increasing rapidly in the developing world. By the year 
2020, it is estimated that CVD will surpass infectious diseases as the world's 
leading cause of death and disability.  
 
Atherosclerotic vascular disease (ASVD), which encompasses coronary 
heart disease, creberovascular disease, and peripheral arterial disease, is 
responsible for the majority of cases of CVD in both developing and developed 
countries. 
 
In Atherosclerosis the lipids and fibrous materials are accumulated in 
coronary arteries. It will progress the atherosclerosis and enhance the cardio 
vascular diseases. The link between lipid metabolism and atherosclerosis 
dominated the thinking until the 1980s. Over the last fifteen years, however, a 
prominent role for inflammation in the pathogenesis of atherosclerosis has been 
established (Wood et al., 1980; Haarbo et al., 1990)63, 64. 
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Haarbo et al. found positive associations in women especially after 50 
years of age, between central fat and total cholesterol, triglycerides levels and 
LDL cholesterol and a negative association with HDL cholesterol in 
postmenopausal women. Walton et al .  
 
        The concept that inflammation governs atherosclerosis and its complication 
has provided a new unifying hypothesis of the link between risk factors and the 
cellular and molecular alterations that underlie this disease.  
 
Endothelial injury is the first and crucial step in the pathogenesis of 
atherosclerosis. A plethora of genetically determined and epigenetic factors, such 
as oxidized low-density lipoprotein (LDL), free radicals (e.g., due to cigarette 
smoking), hypertension, diabetes mellitus, elevated plasma homocysteine, 
infectious microorganisms, autoimmune reactions, and combinations thereof, have 
been identified as etiological principles. 
 
 Endothelial injury triggers inflammation with increased adhesiveness and 
activation of leukocytes, platelets, which is accompanied by the production of 
cytokines, chemokines, vasoactive molecules and growth factors (Haarbo et al., 
1989)65. 
 
 Haarbo et al. found positive associations in women especially after 50 
years of age, between central fat and total cholesterol, triglycerides levels and 
LDL cholesterol and a negative association with HDL cholesterol in 
postmenopausal women. Walton et al . 
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 The hallmark of the early atherosclerotic lesion is the Cholesterol ester-
laden (CE-laden) macrophage foam cell. The free cholesterol causes  macrophage 
lesions. This will leads to phospholipids associated events.  
 
Macrophage death by necrosis leads to lesional necrosis, release of cellular 
proteases, inflammatory cytokines, and prothrombotic molecules, which could 
contribute to plaque instability, plaque rupture, and acute thrombotic vascular 
occlusion.  
 
Currently, atherosclerosis is considered as an inflammation-mediated 
disease driven by complex interactions between leukocytes, especially 
lymphocytes and monocytes (collectively termed as peripheral blood mononuclear 
cells or PBMC), platelets and cells of the vessel wall (Carlesson et al., 1986)66. 
 
Literature on regional adipose tissue distribution and metabolism has 
flourished over the past 25 years. They concluded that the, “proportion of 
abdominal adipose tissue is a key correlate; and perhaps driver of the health risk 
associated with overweight and obesity.  
 
Visceral obesity has now been established as being part of a complex 
phenotype including adiposetissue storage dysfunction and ectopic triglyceride 
accumulation in several sites including the liver. 
 
The demonstrated beneficial role of anti-inflammatory drugs in reducing 
the incidence of nonfatal events in many large clinical trials has demonstrated the 
major role of PBMC in the atherosclerotic process.  
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Hence, a potential insight into the mechanistic and signaling pathways that 
leads to inflammatory events in PBMC becomes necessary for tailoring efficient 
therapeutic strategies for CVD (Freedman et al., 1997; Priestley et al 1985)67, 68. 
 
Nazare et al. have reported ethnic differences in risk and prevalence of 
metabolic diseases including obesity. 
 
Taken together, obesity has become an all too common condition in many 
of the world’s industrialized societies today and is continuing to rise at an 
alarming rate.  
 
Although at first sight it might seem that this is simply the result of 
changes to our diet and a dramatic drop in the level of physical activity in recent 
years, the reality is that scientific studies into the causes of obesity show that the 
condition results from a complex combination of factors (Hunaga et al 1986; 
Wang et al., 2011)69, 70. 
 
The important and potentially atherogenic circulating compounds in the 
circulating lipid systemis Apolipoprotein B (ApoB) including low-density 
lipoproteins (LDLs). ApoB is easily oxidized and responsible for inducing an 
inflammatory reaction and leads to the formation of plaques in the arterial wall.  
 
Therefore, the ApoB considered as a marker in the status of pro- and anti-
atherogenic lipoproteins and may serve as a good marker for assessing 
cardiovascular disease (CVD) risk in future. 
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         One such factor which has come under increasing examination over past ten 
years or so is genetics and in particular, the genes involved in the regulation of 
LDL receptor within the body (Hamilton et al 2006; Barter et al., 2006)71, 72. 
 
6. Obesity and thyroid hormones  
Researchers reported that body composition is associated with the levels 
thyroid hormones since thyroid hormones are involved in the basal metabolism 
and thermo genesis. The body metabolism in turn depends on lipid levels, glucose 
metabolism, food intake and fat oxidation.  
 
The Apo B gene is located on the short arm of chromosome. ].  
Polymorphism has been found to be associated with generalized and regional 
obesity and an increase in various lipoprotein subfractions (total cholesterol [TC], 
lowdensity lipoprotein cholesterol [LDL-C], and triglycerides [TG]), but the 
results are conflicting.  
 
Apo B gene variations in persons with varying lipid levels will cause 
obesity. ( Faraj et al., 2006; Chatziste et al., 2013)73, 74. 
 
Hypothyroidism characterized with low levels of thyroid hormones causes 
an increase in the body weight and decrease in basal metabolism and 
thermogenesis. Several single nucleotide polymorphisms in the Apo B gene have 
been described (Biersac et al 1991)75. 
 
26 
 
There is an inverse correlation between total thyroxine (tT4) values and 
body mass index (BMI), even when T4 values remain in the normal range. 
 
 Abnormalities in thyroid function may be secondary to body weight. 
Increased rate of convertion of T4 to T3 in obese patients which plays as a 
defense mechanism by the high levels of expenditure of energy and increased 
basal metabolic rate75. 
 
 Abnormalities in lipid levels and thyroid hormones in obese patients 
increases the risk of cardiovascular disease and regular monitoring of total 
cholesterol and thyroid hormone levels are mandatory in such patients. 
 
7. Obesity and Renal Function 
Obesity related glomerulopathies are recognized as a complication of 
obesity. Renal biopsies and autopsy studies have reported that focal and segmental 
glomerulosclerosis (FSG) is the commonest histological lesion in obesity patients 
with symptoms of proteinuria . 
 
Many experimental studies also showed the dyslipidaemia is a major 
contributor of renal injury, due to proliferation of mesangial cells and their 
extracellular matrix induced by LDL cholesterol.   
 
In an experimental study done on zucker rats with obesity, researchers 
demonstrated that hyperinsulinemia and hyperlipidaemia leads to 
glomerulosclerosis and progressive renal failure. Chylomicrons, LDL 
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lipoproteins, VLDL are the components of ApoB. These are the ligand for LDL 
receptor to transport the serum cholesterol.  
 
Thus dyslipidemia is as a result in dysfunction of ApoB gene.In ApoB 
gene region many typical sites of single nucleotide polymorphism are observed. 
Deletion and insertion also plays major role. The Insertion/Deletion 
polymorphism is within the first exon. The frequent allele (93bp) encodes a 27 
amino acid peptide (INS; SP-27) and the deletion of 9bp results in 24 amino acid 
peptide (Del; SP-24) (Jemaa et al., 2004)76. 
 
The present study also included the factor of renal failure as a risk factor 
associated with lipid abnormality and Apo B gene polymorphism. Obese patients 
with hypertension are invariably associated with renal involvement because these 
abnormalities are interrelated pathogenically. 
 
8. Obesity with LDL receptor 
 LDL receptor is a Mosaic protein containing 839 amino acids which 
mediates endocytosis of cholesterol rich LDL. Apo – protein B100 is embedded in 
the outer layer of phospholipid. Apo B100 is recognized by LDL receptors. 
 
The apo E protein which is found in VLDL remnants and chylomicrons 
remnants are also detected by LDL receptors. 
 
LDL receptor gene encodes the LDL receptor protein on chromosome 19. 
It is expressed in adrenal cortex and epithelial cells of bronchus. 
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LDL receptor gene also contains 27small nuclear proteins associated with 
increased risk of coronary heart disease. Investigations have shown that the 
correlation among Ins/Del polymorphism and lipid and lipoprotein levels may 
contribute to the pathogenesis of obesity, cardiovascular and non-alcoholic fatty 
liver disease (Vimaleswaran et al 2015)77.  
 
 
 
8.a. Structure 
The Low Density Lipoprotein receptor which contains resides on 
chromosome 19 at the band 19p13.2 and is split into 18 exons that gene produce 6 
isoforms through alternative splicing mechanism.  
 
Coding sequence Exon 1 contains a signal sequence which localizes the 
receptor to the endoplasmic reticulam  for the transport to the cell surface.   
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Exons 2-6 codes the ligand binding region, 7-14 codes the  epidermal 
growth factor (EGF) domain, 15 codes the oligosaccharide rich region, 16 (and 
some of 17) code the membrane spanning region and 18  code the cytosolic 
domain. 
 
LDL receptor family made up of number of domains including 3EGF 
domains, 7LDL- R class A domains and 6LDLR class B domains. LDL receptor 
N-terminal domains involve ligand binding and composed of seven repeat 
sequences.  
 
This repeat sequence called as class A repeat or LDL-A sequence, which 
contains forty amino acids, including repeat disulfide bonds of  six cysteine 
residues.  Each repeat has highly conserved acidic residues used for coordinate a 
single calcium ion. The endosome has acidic interior.  
 
Coordinated disulphide bonds of calcium are important for the structural 
domain intergration. Ligand binding domain is EGF precursor homology domain, 
which contains three repeat growth factors like A, B and C.  
 
A and B are closely linked with C region. In C- terminal domains contains 
fifty amino acids which involve receptor mediated endocytosis.  
 
Researchers demonstrated that the Del allele is associated with decrease 
secretion and increase degradation of Apo B.  (Peacock et al., 1995)78. 
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Seven member of LDL receptors in mammals include   
i. LDL Receptor  
ii. VLDL receptor  
iii.  Apo ER2 
iv. LDL R – Related Protein -4 
v. LDLR- Related protein 1 
vi. LDLR – related Protein 1b 
vii. Megalin.  
 
8.b. LDL Receptor Gene Mutation  
LDL receptor gene mutation cause familial hyperchosterolaemia.  LDL 
receptor mutation broadly classified into 5 types 
 
They are  
1. Class - 1 mutation – LDL receptor synthesis affected in  the endoplasmic 
reticulum (ER). 
2. Class - 2 mutations - inhibit the transport to the Golgi body needed for post  
     translation modification to the receptor  
3. Class -3 mutations - inhibit the binding of LDL to the receptor.  
4. Class - 4 mutations inhibit the internalization of the receptor-ligand complex.  
5. Class -5 mutations causes receptors that cannot recycle properly.  
 
8.c. Functions of LDL Receptor Gene  
LDL receptor mediates the endocytosis of cholesterol and it is maintain 
plasma LDL level. This occurs in all nucleated cells but liver mainly involves 
31 
 
70% of LDL removed from blood circulation. LDL receptors contains clustered in 
clathrin coated pits which form coated endocytic vesicles that carry LDL into the 
cell.   
 
After internalization, the receptors dissociate from their ligands and 
receptor folds to obtain a closed conformation and recycles to the cell surface.   
 
This recycling of LDL receptors provides an efficient mechanism for 
delivery of cholesterol to cell. LDL receptors proteins are synthesized by 
ribosomes on the endoplasmic reticulum and post translational modified by Golgi 
apparatus before travelling in vesicles to the cell surface.  
 
 Study of Benhizia et al. The allele carriers of rat hapetoma cells when 
compared with Del/ Del genotype shows the increased levels of serum VLDL and 
TG(Watts et al., 2000)79.  
 
Materials & Methods 
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MATERIALS AND METHODS 
 
 This observational study conducted from February 2016 to June 2017 was 
started after getting approval from the Institutional Ethical Committee at Karpaga 
Vinayaga Institute of Medical Science Maduranthagam. 
 
 
INFORMED CONSENT 
 An informed consent was obtained from all the subjects participating in the 
present study. 
 
 The participants of the study were 100 male and female between 18-55 
years, 50 obese patients and 50 non obese patients with hypertension, diabetes 
mellitus, hyper cholestrolism who agree to participate in the study and attending 
general medicine outpatient department and Inpatient Ward in Karpaga Vinayaga 
institute of medical science, Kancheepuram District, Tamil Nadu.  
 
 The participants belong to different religious and socioeconomic 
backgrounds. 
 
           Blood samples of 10ml from each patients fasting lipid profile and LDL 
level estimation LDL receptor gene APO B detection by molecular technique- pcr 
Number of study groups :    Two 
Sample size :  100 
Study design :  Observational study 
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Sponsorship                  :   No 
Conflict of interest         :   Nil 
 
Inclusion Criteria: 
 Obese and non obese patients at the age group of 18 – 55 years, both     
male  and female. 
 Hypertension, Diabetes mellitus, Hyper cholesterolism. 
Exclusion Criteria: 
 Age less than 18 years and more than 55 years.  
 Emergency care metabolic diseases patients. 
 
General Information 
 The general information of all the participants such as age, education, 
marital status, occupation and  income were obtained. Detailed history of the 
participants such as past medical history, surgical history, menstrual history, 
obstetric history, personal history and family history were collected through  
personal interview method. 
 
Anthropometry 
 Anthropometric measurements viz. height (cm) and weight (kg), were 
recorded. The height was measured using anthropometric rod to nearest 0.1 cm. 
The subjects were weighed on portable platform weighing balance to nearest 0.5 
kg with ordinary clothes.  
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BMI was calculated by using the formula expressed as the ratio of weight 
in kgs to height in square meters. 
 BMI=weight(kg)/Height(m2)     
 BMI classification for adult Asians (WHO) 
 
 Under weight Ideal BMI 
Over 
weight 
Obese 
grade I 
Obese grade 
II 
BMI <18.5 18.5 – 22.9 23- 24.9 >25-29.9 >30.0 
 
BLOOD PRESSURE 
 After a rest of 15 min, blood pressure (BP) of each of the participants was 
measured by auscultatory method with a standardized calibrated mercury 
sphygmomanometer, in sitting position, in the right arm. The appearance of sound 
(phase 1) is used to define systolic blood pressure (SBP).  
 
 The disappearance of sound (phase 2) is used to define diastolic blood 
pressure (DBP). Two readings were taken at five min interval and average of the 
two values was as blood pressure at that moment. 
 
BIOCHEMICAL PARAMETERS 
 Serum fasting and postprandial plasma glucose, lipid profile, thyroid 
function tests and LDL receptor ApoB gene expression were the biochemical 
parameters estimated in the study population. 
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COLLECTION OF BLOOD SAMPLE 
 The blood samples of the respondents were collected after an overnight 
fast, 1ml in sodium fluoride coated sugar tubes and 3ml in plain tubes between 8 
am to 9 am. 1 ml of blood for postprandial blood sugar was collected 2 hrs after 
breakfast.  
 
 The blood drawn was allowed to coagulate and the serum was separated by 
centrifuging and stored at -20°C until assayed. 
 
Apparatus and glassware 
 All glassware used for the experiments were thoroughly washed initially 
detergent solution and then washed with double distilled deionized water three 
times and dried before used.  
 
 All precautionary measures were taken to prevent contamination during all 
stages of procedure. 
 
 All colorimetric readings were taken using colorimeter. 
 
MEASUREMENT OF BLOOD GLUCOSE 
METHOD: GOD/POD METHOD 83 
PRINCIPLE 
 Glucose is oxidized by glucose oxidase (GOD) into gluconic acid and 
hydrogen peroxide. This hydrogen peroxide then reacts with phenolic compound/ 
amino antipyrine in the presence of peroxides to form a highly red coloured 
quinonaeamine.  
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 The intensity of the red colored compound is proportional to the glucose 
concentration and is measured at 505 nm. The final colour is stable for 2 hours. 
   GOD 
Glucose + O2      Gluconic acid + H2O2 
 
             POD 
H202 + Phenolic Compound + 4 Aminoantipyrine              Red Compound + 2 H20 
 
REAGENTS REQUIRED 
Phosphate Buffer        - 95 mmol/L 
4 Aminoantipyrine - 0.2 mmol/L 
P- Hydroxyl Benzoic Acid - 5.9 mmol/L 
Glucose Oxidase      - >5000U/L 
Peroxidase               - >5000U/L 
Glucose Standard                  - 1 g/L 
 
REAGENT RECONSTITUTION 
 Gently dissolve one tablet in 20 ml of distilled or deiodinised water in 
clean beaker with continuous stirring. Transfer the solution into a dark bottle. 
Write the reconstitution date on the label provided. This is stable for 6 weeks 
when stored at 2o-8°C.  
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PROCEDURE 
 Blank Standard Test 
Working Solution 1 ml 1 ml 1 ml 
Standard - 10 µl - 
Sample - - 10 µl 
 
Incubate for 15 min at 37°C. Mix and read. 
 
MEASUREMENT OF SERUM TOTAL CHOLESTEROL 
METHOD: CHOLESTEROL OXIDASE AND PEROXIDASE METHOD 84 
PRINCIPLE 
 Cholesterol esterase hydrolyses esterified cholesterols to free cholesterol. 
The free cholesterol is oxidized to form hydrogen peroxide which further reacts 
with phenol and 4-aminoantipytine by the catalytic action of peroxidase to form a 
red colored quinoneimine dye complex. Intensity of the color formed is directly 
proportional to the amount of cholesterol present in the sample. 
 
REAGENTS 
REAGENT 1 (ENZYMES / CHROMOGEN) 
Cholesterol esterase - ≥ 29 U/L 
Cholesterol oxidase - ≥ 240 U/L 
Peroxidase - ≥ 1000 U/L 
4-Aminoantipyrine - 0.5 mmol/L 
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REAGENT 1A (BUFFER) 
Pipes buffer, pH 6.95 - 50 mmol/L 
Phenol - 24 mmol/L 
Sodium cholate - 0.5 mmol/L 
 
STANDARD (CHOLESTEROL 200 mg/dl) 
 Cholesterol - 2 g/L 
 
REAGENT RECONSTITUTION 
 Allow the reagents to attain room temperature. Dissolve the contents in one 
bottle of reagent 1 with the contents in one bottle of reagent 1A. Mix by gentle 
swirling and write the date of reconstitution in the label provided. Wait for 5 min 
before using. This is stable for 3 months when stored at 2°C - 8°C 
 
PROCEDURE 
 Blank Standard Test 
Working Solution 1 ml 1 ml 1 ml 
Standard - 10 µl - 
Sample - - 10 µl 
  
Incubate for 5 min at at 37oC. Mix and read in a semi auto analyser 
programmed as an end point reaction with an increasing slope. 
 
NORMAL VALUE:  Serum: 130 – 250 mg/dl 
LINEARITY:   
 The procedure is linear up to 1000 mg/dl. If the value exceeds this limit, 
dilute the serum with normal saline and repeat the assay. Multiply results by 
dilution factor.  
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MEASUREMENT OF SERUM HDL 
METHOD: PHOSPHOTUNGSTATE METHOD 84 
PRINCIPLE 
 Chylomicrons, VLDL (very low density lipoproteins) and LDL (low 
density lipoproteins) fractions in serum are separated from HDL (high density 
lipoproteins) by precipitating with phosphotungstic acid and magnesium chloride. 
The HDL fraction of cholesterol which remains in the supernatant, After 
centrifugation is assayed with the enzymatic cholesterol method using cholesterol 
esterase, cholesterol oxidise, peroxidise and the chromogen. 
 
REAGENTS 
REAGENT 1 (ENZYMES / CHROMOGEN) 
Cholesterol Esterase -  ≥ 30 U/L 
Cholesterol Oxidase -  ≥ 250 U/L 
Peroxidase -  ≥ 1000 U/L 
4-Aminoantipyrine -  0.5 mmol/L 
 
REAGENT 1A (BUFFER) 
Pipes buffer, pH 6.95 -  50 mmol/L 
Phenol -  24 mmol/L 
Sodium cholate -  0.5 mmol/L 
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REAGENT 2 (PRECIPITATING REAGENT) 
Phosphotungstic acid -  2.4 mmol/L 
Magnesium chloride -  39 mmol/L 
 
STANDARD (HDL CHOLESTEROL 50 mg/dl) 
 Cholesterol - 0.5 g/L 
 
REAGENT RECONSTITUTION 
 Allow the reagents to attain room temperature. Dissolve the contents in one 
bottle of reagent 1 with the contents in one bottle of reagent 1A. Mix by gentle 
swirling till completely dissolved.  
 
 Write the date of reconstitution in the label provided. Wait for 5 min before 
using. The reconstituted reagent is stable for 3 months when stored at 2°C - 8°C. 
 
PROCEDURE 
Reagent Test 
Sample 0.20 ml 
Precipitating Reagent 2 0.20 ml 
  
 Dispense into a centrifuge tube, 0.20 ml of serum and 0.20 ml of the 
precipitating reagent. Mix well and centrifuge at 3500-4000 rpm for 10 min. 
Separate the supernatant immediately and determine the cholesterol content. The 
HDL cholesterol standard should not be subjected to the precipitation step. 
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CHOLESTEROL PROCEDURE 
 Blank Standard Test 
Working Solution 1 ml 1 ml 1 ml 
Standard - 20 µl - 
Sample - - 20 µl 
 
 Incubate for 5 min at 2°C - 8°C. Mix and read in a semi auto analyser 
programmed as an endpoint reaction with an increasing slope. 
 
MEASUREMENT OF SERUM TRIGLYCERIDE 
METHOD: ENZYMATIC COLORIMETRIC METHOD 85 
PRINCIPLE 
 Lipoprotein lipase hydrolyses triglycerides to glycerol and free fatty acids. 
The glycerol formed with adenosine triphosphate (ATP) in the presence of 
glycerol kinase forms glycerol 3 phosphate which is oxidised by the enzyme 
glycerol phosphate oxidase to form hydrogen peroxide. The hydrogen peroxide 
further reacts with phenolic compound and  4-aminoantipyrine by the catalytic 
action of peroxidise to form a red coloured quinoneimine dye complex. Intensity 
of the colour formed is directly proportional to the amount of triglyceride present 
in the given sample. 
 
 The intensity of the purple colour is directly proportional to the 
triglycerides concentration and is measured at 546 nm. 
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NORMAL VALUES: 
 Serum/plasma  : Suspicious : 150 mg/dl and above 
    Elevated : 200 mg/dl and above 
 
REAGENTS 
REAGENT 1 (ENZYME / CHROMOGEN) 
Lipoprotein lipase -  ≥ 1100 U/L 
Glycerol kinase -  ≥450 U/L 
Glycerol3phosphate Oxidase -  ≥ 5000 U/L 
Peroxidase -  ≥ 350 U/L 
4-Aminoantipyrine -  0.7 mmol/L 
ATP -  0.3 mmol/L 
Reagent 1A (Buffer) 
Pipe’s  buffer, pH 7.0 -  50 mmol/L 
ADPS -  0.9 mmol/L 
Magnesium salt -  17.8 mmol/L 
REAGENT RECONSTITUTION 
 Allow the reagents to attain room temperature. Dissolve the contents of one 
bottle of reagent 1 with one bottle of reagent 1A. Mix by gentle swirling and write 
the reconstitution date on the label provided. This is stable for 6 weeks when 
stored at 2o C - 8o C. 
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PROCEDURE 
 Blank Standard Test 
Working Solution 1 ml 1 ml 1 ml 
Standard - 10 µl - 
Sample - - 10 µl 
 
 Incubate for 5 min at 37°C. A purple colour develops. Mix and read at 546 
nm in a semi auto analyser programmed as endpoint reaction with an increasing 
slope. 
 
CALCULATION OF LDL 
 Serum total cholesterol was estimated by cholesterol oxidase and 
peroxidase method, serum HDL-Cholesterol by phosphotungstate method, serum 
triglycerides by enzymatic colorimetric method. From the values of total 
cholesterol, HDL-cholesterol and triglycerides, 
 
 LDL-cholesterol can be calculated using the Friedewald’s formula. 
 Friedewald Formula = T.Cholesterol - (HDL + TGL / 5) 
 where TGL/5 is the concentration of VLDL cholesterol. 
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ESTIMATION OF SERUM CREATININE  
METHOD: JAFF’S METHOD 
KIT NAME: BioSystems 
PRINCIPLE 
 Creatinine in alkaline medium reacts with picrate to form an orange – red 
complex. Under specific conditions of the assay, the rate of development of the 
colour is proportional to the concentration of creatinine in the sample when 
measured at 500nm (490 – 510nm). 
 
REAGENT 
Reagent 1 :  Picric acid 34.9 mmol/L 
  Sodium hydroxide 45 mmol/L 
Reagent 2 :  Sodium hydroxide 0.26 mol/L 
  Creatinine Standard – 2 mg/L 
 
 Preparation of working reagent – All reagents are brought to room 
temperature before use. Equal volumes of reagent 1 and 2 are mixed in a clean test 
tube. The working solution is stable for 3 days at 15 – 25° C. 
 
PROCEDURE 
 The working reagent, standard and samples were brought to room 
temperature before the test. Working reagent 1ml and creatinine standard 100 µL 
are dispensed into a test tube and read immediately for factor calculation in a RA-
50 Semi-automatic analyzer. After calibration 100 µL of serum of a subject was 
added to 1 ml of   working reagent and read immediately to get the serum 
creatinine value for that subject. 
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MEASUREMENT OF SERUM BUN – BY UREASE METHOD 84 
PRINCIPLE 
 Urea is hydrolysed  in the presence of water and urease to produce 
ammonia and carbon dioxide. The ammonia produced combines with α-
Ketoglutarate and NADH in the presence of glutamate dehydrogenase to yield 
glutamate and NAD. The amount of urea nitrogen may be calculated by 
determining the absorbance decrease per minute relative to urea nitrogen standard 
at 340 nm. 
 
REAGENTS 
Reagent 1 (Enzymes) : ADH 0.7 mmol/L 
     GLDH  ≥ 1000 U/L 
     Urease ≥ 30000 U/L 
     NADH 0.3 mmol/L 
     Α- Ketoglutarate        9 mmol/L 
 
Reagent 2 (Buffer)  :  Standard (BUN 20 mg/dL): 
     Urea                             0.428 g/L 
PROCEDURE 
 Standard Test 
Reagent 1000 µl 1000 µl 
Standard 10 µl - 
Sample - 10 µl 
 
Mix and read immediately. 
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CALCULATION 
  BUN value X 2.14  = Urea 
THYROID HORMONE ASSAY 
The blood samples of all the participants were collected after an overnight 
fast and  all following parameters were estimated on the day of collection. 
1. T3 assay 
2. T4 assay 
3. TSH assay 
 
ASSAY OF TOTAL T3  
Total T3 assayed in serum according to method of Timothy J. Wilke 1986 86. 
Principle 
In the type of enzymatic immune assay, the competitive reaction between 
enzyme antigen and native antigen is present. They conjugate for a selected 
number of binding sites which are insoluble. Immobilized T3 antibody, native T3 
antigene, are main reagents for this assay.  
 
TBG and T3 enzyme which bind to serum proteins are measured.  This 
method achieves this goal. The fraction of the enzyme bound antigen or native 
antigen from the sample that does not bind to the coated well is washed away.  
 
The substrate is added to the antigen concentration. The enzyme activity 
between antigen and antibody is inversely proportional to antigen concentration 
which is measurable.  
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Assay Protocol 
 Before starting the assay, allow all the serum reference and controls to 
reach room temperature [21-25°c].  
 Format the micro plate wells for each calibrator and patient specimen to be 
assayed. Replace the unused micro well strips back in the aluminum foil, 
seal and store at 2-8°c.  
 Id 50µl of the calibration and the patient specimen to assigned well. 
 Add 100µl of  T3enzyme conjugate to each well. Care should be taken to 
dispense the entire reagent to the bottom of the coated well 
 Shake the micro plate gentle for 20-30 seconds to mix and cover. 
 Incubate for 60 minutes at room temperature [21-25°c]  
 Aspirate the contents of the wells and fill them completely [approximately 
300ul] with the diluted washing solution. Repeat the washing procedure 
two times. After the last wash, blot the micro plate on absorbent tissue to 
remove excess liquid from wells.  
 Add 100µl of working substrate solution to all the wells add the reagents in 
the same order which minimize reaction time difference.  
 Incubate for 15 mins at room temperature.  
 Add  50µl of stop solution to each well and mix well for 15-20 seconds. 
 In a microplater redder at 450 nm, the absorbace is read.  
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ASSAY OF TOTAL T4  
 T4 assayed in serum according to the method of young. D.S.,et al [1975] 
and modified by   Stjernholm, Mr., et al [1977]86. 
 
Principle  
 In a competitive EIA, there exists a competitive reaction between native 
antigen and enzyme – antigen conjugate for a limited number of insolubilized 
binding sites on the antibody coated on the micro well. After the antigen, 
antibody reaction has taken place, the fraction of the antigen in the conjugate or 
native antigen from the sample, which does not bind to the coated well, is washed 
away.  
 
The enzymatic activity in the antibody bound fraction, which is inversely 
proportional to the native antigen concentration, is measured by addition of the 
substrate. By utilizing calibrators of known antigen values, a dose response curve 
can be generated from which the antigen concentration in a sample can be found 
out. 
 
Assay Protocol 
 Before starting the assay, allow all the reagents serum references and 
controls to reach room temperature (21-25°c). 
 
 Format the micro plate wells for each calibrator and patient specimen to be 
assayed. Replace the unused micro well strips back in to the aluminium foil, seal 
and store at 2-8°c. 
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 Add 50µl of the calibrator and the patient specimen to assign well. 
 Add 100µl of T3 enzyme conjugate to each well. Care should be taken to 
dispense the entire reagent to the bottom of the coated well. 
 Shake the micro plate gentle for room temperature(21-25°c) 
 Aspirate the contents of the wells and fill them completely (approximately  
300µl) with the diluted washing solution. Repeat the washing procedure 
two times. After the last wash, blot the micro plate on absorbent tissue to 
remove excess liquid from wells. 
 dd 50µl of stop solution to each well at 450nm (using a reference wave 
length of 620-630nm to minimize well imperfections) in a micro plate 
reader. 
 
ASSAY OF TSH 
 Serum TSH assayed in according to the method of Spenser. CA, et al 
(1995) and modified by fisher D.A. (1996)87. 
 
Principle 
 In a quantitative EIA, high affinity antibodies react with antigen to from an 
insoluble sandwich complex on the surface of a coated micro plate.  
 
 The antigen from the specimen gets linked at the surface of the well 
through interaction of reaction IgG coated on the well and affinity purified x-
antigen IgG conjugated with HPR. X antigen fraction immune globulin G is 
conjugated with enzyme.  
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 If it is not bind to coated well washed thoroughly. The enzyme activity, 
which is proportional to antigen concentration in the sample, is measured by 
addition of substrate. From the known antigen value the response curve is 
produced.  
 
 Thus the antigen concentration in a sample can be easily measured from 
the curve. 
 
Assay Protocol 
 Before starting the assay, allow all the reagents serum references and 
controls to reach room temperature (21-25°c). 
 Format the micro plate wells for each calibrator and patient specimen to be 
assayed. Replace the unused m00icro well strips back in to the aluminium 
foil, seal and store at 2-8°c. 
 Add 50µl of the calibrator and the patient specimen to assign well. 
 Add 100µl of T3 enzyme conjugate to each well. Care should be taken to 
dispense the entire reagent to the bottom of the coated well. 
 Shake the micro plate gentle for room temperature(21-25°c) 
 Aspirate the contents of the wells and fill them completely (approximately 
300µl) with the diluted washing solution. Repeat the washing procedure 
two times. After the last wash, blot the micro plate on absorbent tissue to 
remove excess liquid from wells. 
 Add 100µl of working substrate solution to all the wells.  
 Incubate at room temperature (21-25°c) for fifteen (15) minutes. 
 Add 50µl of stop solution to each well for 15-20 seconds. 
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 Read the absorbance in each well at 450nm (using a reference wave length 
of 620-630nm to minimize well imperfections) in a micro plate reader. 
 
EXTRACTION OF GENOMIC DNA FROM WHOLE BLOOD 88 
The protocol is simple and fairly rapid. The organic solvents are not used. 
But it is used to precipitate contaminated protein in salt extraction. The DNA 
extracted from it is readily used in PCR techniques. One can obtain approximately 
100-200 ug of DNA from 4-8 ml of fresh or frozen whole blood. 
 
Reagents 
Buffer A (Red blood cell lysis buffer) composition 
 0.32 M sucrose 
 10 mMTrisHCl 
 5 mM MgCl2 
 0.75% Triton-X-100 
Adjust pH to 7.6 
Buffer B (Proteinase K buffer) composition 
 20 mMTris-HCl 
 4 mM Na2EDTA 
 100 mMNaCl 
Adjust pH to 7.4 
All solutions should be sterile. Autoclaved is done to Buffer A. Then add Triton  
X - 100 
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Procedure 
1. Tke 4ml of blood with this and add 4ml of buffer A and sterile, distilled, 
cold deionized water of 8ml. 
2. Vortexed gently or invert tube 6-8 times and leave to incubate on ice for 2-
3 minutes. 
3. Spined at 3500 rpm for 15 minutes at 4oC. The supernatant is added to 
2.5% bleach solution. To the vertexed pellet add 6ml of water and 2ml of 
buffer A.  
4. Spined at 3500 rpm for 15 minutes at 4oC. The pellet should be white to 
cream in color. If the pellet still appears red, continue the washing process.   
5. To the pellet add 5ml of buffer B and 500 µl of 10% sodium dodecyl 
sulfate. Re-suspend pellet by vortexing vigorously for 30-60 seconds.  
6. Then added 50 µl of Proteinase K solution (20mg/ml). Prepare fresh 
proteinase K solution and refrigerate the solution.  
7. In a water bath of 55oC incubate the solution for 2 hours. Remove samples 
and leave to cool to room temperature (or leave for 2-3 minutes on ice).  
8. Added 4 ml of 5.3 M NaCl solution. Vortex gently for 15 seconds. 
9. Spined at 4500 rpm for 15-20 minutes at 4oC. Pour off supernatant into a 
fresh tube. Take care not to dislodge pellet.  
10. Added an equal volume of cold isopropanol (stored at -20oC). Invert 5-6 
times gently to precipitate DNA. 
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11. Remove DNA with a wide bore tip and transfer to a micro centrifuge tube. 
Wash with 1 ml of 70% ethanol. Leave DNA to dry for 15-20 minutes at 
37oC.  
12. Re-suspend in 300-400 µl of TrisHCl, pH 8.5 (not TE!). Leave to re-
dissolve overnight at room temperature. DNA can be safely refrigerated for 
up to a year. Long-term storage may involve ethanol at -70oC. 
 
VERIFYING DNA EXTRACTION BY GEL ELECTROPHORESIS  
10 X TBE buffer: 
 Tris base - 54 gm 
 Boric acid - 27.5 gm 
 0.5 M EDTA (pH 8) - 20 ml 
 Make upto 500ml using dH2O water 
 
6X Tracking Dye (10 ml): 
 Bromophenol blue (0.25%) 
 Xylene cyanol (0.25%) 
 Glycerol (30%) – 6 ml 
 Make upto 10ml using autoclaved dH2O water. 
 
Protocol 
1. Prepared 1% of Agarose gel by adding Agarose in 1X TBE buffer. 
2. Melted it in microwave oven until the Agarose uniformly dissolved in 
the buffer. 
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3. Added 2μl of Ethidium bromide to the Agarose solution and pour it on 
a clean gel platform and place the comb and set it aside to solidify.  
4. Placed this set up in an electrophoresis tank containing 1X TBE buffer, 
pull out the comb. 
5. Mixed the PCR product with tracking dye and load the mixture in the 
Agarose well. 
6. Electrophoresis was done at 100 – 150V until the tracking dye reaches 
75% of gel. 
7. Analyzed the DNA bands using GEL DOC.  
 
PCR SETUP PREPARATION  
After DNA extraction verification by Gel electrophoresis, the extracted 
DNA is amplified. 
Components Volume 
PCR Master Mix 25μl 
Primer FP1/FP2 (100μMl) 2μl 
Primer RP1/RP2 (100μMl) 2μl 
Sample 1μl of Extracted DNA Sample 
H2O Up to 5μl 
 
Set of Primers 
Upstream primer 5’- 
GGAGACTATTCAGAAGCTAA-3’ as 
and  downstream primer 5’-
GAAGAGCCTGAAGACTGACT-3’ as. 
Validated with 10 
samples DNAs 
from the thesis 
subjected sample. 
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PCR SETUP CONDITIONS 
CYCLE Steps 
1 Step 2 step 
Cycles 
Temperature Time Temperature Time 
Initial denaturation 98°C 2 min 98°C 2min 1 
Denaturation 
Annealing 
Extension 
98°C 
- 
72°C 
15 s 
30 s 
30 s 
98°C 
56°C 
72°C 
15 s 
30 s 
30 s 
 
35 
Final extension 72°C 3 min 72°C 3min 1 
 
DNA PREPARATION FOR SEQUENCING (Pre-Sequencing) 
Required reagents 
1. ddNTPS -"A" ddATP, "G"ddGTP,"T" ddTTP, "C"ddCTP, 
2. All four dNTP's  
3. DNA polymerase 
4. Template 
5. Primer set 
6. MQ water 
 
As the DNA is synthesized, nucleotides are added on to the growing chain 
by the DNA polymerase. In a normal nucleotide some occasion dideoxynucleotide 
will be incorporated. This leads in chain termination. The fragment of CT, CTA, 
and CTAT and so on, are thus generated. All these fragments are then undergone 
gel electrophoresis based on their length (Mol.Wt) in the machine capillaries.   
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The laser detector detects the corresponding fluorescent nucleotide and translates 
into the colored peaks called as chromatogram.  
 
PCR PRODUCT PURIFICATION FROM GEL 
(using EZ10 spin column DNA Gel Extraction Kit- Biobasicinc) 
1) Added 700 µl of binding buffer II to the gel piece in eppendorf. 
2) Kept in water bath at 55ºC for 20 min.  
3) Added 100 µl of Isopropanol to that and mix well by inverting tube. 
4) Transferred the solution into spin column and let it stand for 2 min 
5) Centrifuged at 12000 rpm for 1 min. Discard the filtrate.  
6) Added 500 µl of wash solution to the column and centrifuge at 12000 rpm 
for 1 min. Discard the filtrate. (Repeat step 6) 
7) Empty spin of the column was done. 
8) Added 25 µl of elution buffer in the center of the column placed on a fresh 
tube. 
9) Incubated at RT for 2 min. 
10) Spined at 12000 rpm for 1 min. 
11) Removed the filter column and store DNA content at 40 C. 
 
CYCLIC PCR 
 In cyclic PCR the chain termination reaction takes place to generate the 
fragments to be visualized in the sequencing machine. 
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Primers for all amplification of LDL receptor exon  
PCR 
Mix 
Amplified 
Region Forward Primer Reverse Primer 
Frag 
Size 
(bp) 
A 
Promoter CAGCTCTTCACGGGAGACC 
ACCTGCTGTGTCCTAG
CTGG 287 
Exon 1 CACATTGAAATGTAATGAGG 
CTATTCTGGCTGGAGC
AAGCC 215 
EXON 5 AGAAAATCAACACACTGTGTCCTG 
GGAAAACAAGCEAGAT
GGCCAGCG 180 
B 
EXON 9 CCTGACCTCGCTCCCCGGACCCCCA 
GGCTGCAGGCAGGGC
GACGCTCAC 223 
EXON 2 TTGAGAGACCCTTTCTCCTTTTCG 
GCATAATCATGCCCAA
AGGGG 183 
EXON 16 CCTCCTTTAGACCTGGGCC 
CAAAGCGGGGAGGCT
GTGAC 173 
 
 PCR amplified product was digested with AvaII generate exon containing 
157bp and 280bp sub fragments for single stand polymorphism analysis.  
 
Statistical Analysis 
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STATISTICAL ANALYSIS 
 
 The individual student‘t’ test was done to evaluate the significance of 
difference of means of two groups, using SPSS (statistical package for social 
science) statistical package, version 17. The data’s were also subjected to 
independent samples test (unpaired) where ever necessary to evaluate the 
significance of difference of mean of control and study groups using SPSS 
software. The values are presented as mean +SD and p valve <0.05 was 
considered significant. 9ZarJH., 1984)89 
 
 
Results 
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RESULTS 
 
 The present study was conducted in the Department of Biochemistry, 
Department of Medicine at Karpaga Vinayaga Institute of Medical Science, 
Maduranthagam. The individuals enrolled in the study were grouped into two 
based on their BMI and blood pressure values. 
 Obese  Group (50) 
 Non Obese Group (50)  
 
 The obese and the non – obese subjects were all between 18 and 55 years 
of age. The age distribution in four ranges namely, 18-30, 31-40, 41-50 and 51-55 
in the obese group and non- obese group is given in Figure 1 and Table 1.   
 
FIGURE .1. CASE DISTRIBUTION IN RELATION TO AGE 
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Table.1. CASE DISTRIBUTION IN RELATION TO AGE 
Age 
Groups 
Obese 
Group 
Non-Obese 
Group 
Tot
al 
Obese 
Group (%) 
Non-Obese 
Group (%) 
Total 
(%) 
18- 30 
years 3 8 11 6.00 16.00 11.00 
31-40 
years 16 13 29 32.00 26.00 29.00 
41-50 
years 18 19 37 36.00 38.00 37.00 
51-55 
years 13 10 23 26.00 20.00 23.00 
Total 50 50 100 100.00 100.00 100.00 
 
 
Age Distribution Obese Group Non-Obese Group Total 
Mean 44.08 42.64 43.36 
SD 8.45 9.28 8.86 
P value 
Unpaired t Test 0.4189 
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The gender distribution in the two groups is given in  Figure 2 and Table 2. 
In obese subjects age and gender there was no significant compared with non-
obese subjects (P values of age and gender is 0.4189 and 0.0718 respectively). 
 
FIGURE. 2. CASE DISTRIBUTION IN RELATION TO GENDER 
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Table. 2. CASE DISTRIBUTION IN RELATION TO GENDER 
Gender 
Status 
Obese 
Group 
Non-
Obese 
Group 
Total 
Obese 
Group 
(%) 
Non-
Obese 
Group 
(%) 
Total 
(%) 
Male 21 30 51 42.00 60.00 51.00 
Female 29 20 49 58.00 40.00 49.00 
Total 50 50 100 100.00 100.00 100.00 
P value 
Chi Squared Test 0.0718 
 
The parameters analyzed in all the subjects were 
1. Blood Glucose 
2. Serum Lipid Profile  
3. Serum Urea  
4. Serum Creatinine 
5.  Serum Thyroid Profile  
 
The results expressed in their respective units are given in the master sheets 
at the Annexure I 
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RANDOM BLOOD SUGAR AND OBESE  
 Figure 3 and Table.3 shows the relation between the blood glucose levels 
in obese and non obese patients. The blood levels of random glucose were 
observed in both the groups of patients. The levels of random glucose were found 
to be significantly (p <0.02) increased in non obese patients. The concentrations 
of random blood sugar were expressed as mean±SD in Table 4 
 
Figure. 3. Random Blood sugar in obese and non obese patients 
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Table.3. Random Blood sugar in obese and non obese patients 
Random  
Blood Sugar  
Groups 
Obese 
Group 
Non-Obese 
Group Total 
Obese  
Group  
(%) 
Non-Obese  
Group 
(%) 
Total  
(%) 
≤ 100 mg/dl 17 24 41 34.00 48.00 41.00 
101-150 mg/dl 23 21 44 46.00 42.00 44.00 
151-200 mg/dl 5 4 9 10.00 8.00 9.00 
201-250 mg/dl 3 1 4 6.00 2.00 4.00 
251-300 mg/dl 2 0 2 4.00 0.00 2.00 
Total 50 50 100 100.00 100.00 100.00 
 
Random Blood Sugar  
Distribution Obese Group Non-Obese Group Total 
Mean 124.47 106.34 115.41 
SD 12.26 11.73 40.14 
P value 
Unpaired t Test 0.0232 
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BLOOD PRESSURE WITH OBESE AND NON OBESE PATIENTS  
 Figure. 4 and Table.4. Shows that the relation between the blood pressure 
levels in obese and non obese patients.  The levels of systolic and diastolic blood 
pressure were observed in both the groups.  The mean SBP and DBP for the study 
participants with obese were 142.60±13.69 and 82.64±11.88 mmHg and with non 
obese were 118.20±18.92 and 79.32 ±10.7 in mmHg respectively as shown in 
Table 4. The observed results clearly depicts that the blood pressure was found to 
be significantly (p <0.05) decreased in non obese patients when compared to 
obese patients 
 
Figure.4. Blood Pressure in obese and no obese patients 
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Table.4. Blood Pressure in obese and non obese patients 
 
Blood Pressure SBP (mm Hg) DBP (mm Hg) 
Obese Group 
Mean 142.60 82.64 
SD 139.69 11.88 
Non-Obese Group 
Mean 118.20 79.52 
SD 18.92 10.71 
P value 
Unpaired t Test 0.2239 0.1709 
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LIPID PROFILE IN OBESE AND NON OBESE  
 Figure 5 and Table.5. illustrates the levels of Total Cholesterol (TC), 
Triglycerides (TGL) were significantly increased and decreased in High Density 
Lipoprotein (HDL) in obese patients when compared with non obese patients.  
The levels of LDL and VLDL  were found to be significantly decreased (P<0.001) 
in non -obese patients when compared with obese patients.  The concentrations of 
TC, TGL, HDL, LDL, VLDL in mg/dl for the study sample were expressed in 
Table 5. 
 
Figure.5. Lipid profile in obese and non obese levels 
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Table.5. Lipid profile in obese and non obese levels 
Lipid  
Profile 
Total 
Cholesterol 
(mg/dl) 
Trigly 
cerides 
(mg/dl) 
High 
Density 
Lipo 
protein 
(mg/dl) 
Low 
Density 
Lipo 
protein 
(mg/dl) 
Very 
Low 
Density 
Lipo 
protein 
(mg/dl) 
Obese 
Group 
Mean 237.76 196.00 38.34 147.62 40.38 
SD 56.43 72.77 21.69 69.36 14.34 
Non-
Obese 
Group 
Mean 199.72 164.78 45.27 125.74 35.00 
SD 47.17 85.63 21.27 56.24 23.68 
P value 
Unpaired t Test 0.0004 0.0423 0.1098 0.0864 0.1726 
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RENAL PROFILE IN OBESE AND NON OBESE LEVELS 
Figure 6 and Table.6 shows that the levels of Urea and creatinine levels were no 
significant increased in obese patients when compared with non obese patients.   
 
Figure.6. Renal Profile in obese and non obese patients 
 
 
Table.6. Renal Profile in obese and non obese patients 
Renal Profile Blood Urea (mg/dl) 
Serum Creatinine 
(mg/dl) 
Obese Group 
Mean 32.10 1.05 
SD 12.12 0.94 
Non-Obese Group 
Mean 29.64 0.89 
SD 8.63 0.53 
P value 
Unpaired t Test 0.2452 0.2977 
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THYROID PROFILE IN OBESE AND NON OBESE PATIENTS 
 Figure 7 and Table.7 shows that the levels of TSH levels were 
significantly increased in obese patients when compared with non obese patients 
but there were no significant changes in T3 and T4 levels in obese patients when 
compared with non- obese patients.  
 
Figure.7. Thyroid profile in obese and no obese patients 
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Table.7. Thyroid profile in obese and no obese patients 
 
Thyroid Profile T3 (pg/ml) T4 (microgram /dl) TSH (mIu/ml) 
Obese Group 
Mean 19.96 8.17 3.45 
SD 9.21 3.12 1.37 
Non-Obese Group 
Mean 21.16 9.20 4.47 
SD 9.83 3.90 2.94 
P value 
Unpaired t Test 0.5300 0.1505 0.0286 
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LDL ApoB GENE POLYMORPHISM  
 Figure 8 and Table.8 shows that the LDL ApoB gene polymorphism like 
–ve polymorphism and +ve polymorphism levels. –ve LDL ApoB gene 
polymorphism X negative alleles  were significantly increased in non obese 
patients when compared with obese patients but  +ve  LDL ApoB gene 
polymorphism X Positive alleles were significantly increased in obese patients 
when compared with non obese patients.   
 
Figure.8. LDL Apo B Gene Polymorphism 
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Table.8. LDL Apo B Gene Polymorphism 
 
ApoB Gene 
Polymorphism 
Obese 
Group 
Non-
Obese 
Group 
Total 
Obese 
Group 
(%) 
Non-
Obese 
Group 
(%) 
Total 
(%) 
Polymorphism -
ve 34 46 80 68.00 92.00 80.00 
Polymorphism 
+ve 16 4 20 32.00 8.00 20.00 
Total 50 50 100 100.00 100.00 100.00 
P value 
Chi Squared Test 0.0027 
74 
 
 
 
LDL APOB GENE POLYMORPHISM ALLELES IN OBESE AND NON 
OBESE PATIENTS  
 
Table.9. Indicates that the LDL ApoB gene polymorphism alleles like –ve 
and +ve polymorphism levels were significantly increased in Obese patients when 
compared with non obese patients.  
 
LDL ApoB Gene Polymorphism Obese Group Non-Obese Group 
Polymorphism –ve (X-)  179 
 
168 
 
Polymorphism +ve (X+) 45 56  
P value 
Chi Squared Test 0.001 
 
Discussion 
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DISCUSSION 
 
 Obesity is unhealthy excess of body fat, which increases the risk of 
coronary heart disease.  The prevalence of obesity is increasing in all age groups, 
including older persons.  
 
Age and Sex distribution of obesity with coronary Heart Disease: 
 In the present study the mean obesity  in the four  age groups 18-30, 31-40, 
41-50  and 50 - 55 years were mean of age groups of obese and non obese patients 
was 44.08 + 8.45 and 42.64 + 9.28 years  respectively. Flegal KM et al and 
Mokdad et al showed 20 to 60years of age increase prevalence of obesity and 
decrease after 60 years age.  Though the mean was higher in higher age groups it 
was not statistically significant (p value > 0.05). 
 
 In above 80years old male or female persons, the prevalence of rate of 
obesity is one-half when compared with 50-60years age old due to survival 
advantage of being lean, which makes lean and to develop very old.  
 
BMI and Obesity with  coronary Heart Disease: 
 Body mass index does not involve directly measure the body mass, but also 
to asses health risk factors with being obese. A normal BMI range is 18.5 to 
24.9m. 
 
The prevalence of obesity among the coronary Heart disease patients  in 
the present study was similar to that of the general population in India. In our 
study, 71.7% coronary Heart disease patients of were obese which was almost 
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similar to study conducted in West Bengal in India (Park K. Text book of 
preventive and socialMedicine 19th edition page 335)90. 
 
 The international diabetes foundation has accepted BMI > 25kg/m2 and 
>23kg/m2 as cut off value for obesity for Asian men & women respectively and 
according to this the prevalence of Obesity among males was 32%and among 
females was 52% which was alarming. In the present study in obese patients 
contain high BMI compared with non obese patients.  
 
BLOOD SUGAR AND OBESE 
 In our study, the random blood glucose levels were observed in both obese 
and non-obese patients. The random blood sugar mean levels of obese patients are 
124.47 + 12.26mg/dl and non obese mean values are 106.34 + 11.73mg/dl 
respectively. The levels of random blood glucose were found to be significantly 
increased in obese patients compared with non obese patients.   
 
 Wu L et al., 201391 observed the levels glucose 6- phosphate 
dehydrogenase in obesity induced by high fat diet and also increased in obese rat.  
 
 One mechanism for the signaling defects in obesity may be the high 
activity of protein tyrosine phosphates. It is dephosphorylated and by passing 
through tyrosyl phosphorylation it terminates the signaling. In some data, the 
expression and activity in muscle and adipose tissue of the obese humans and 
rodents indicate that, three PTP’s including, leukocyte antigen related phosphate, 
src-homology-phosphate 2 and PTP1B levels are increased.  
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BLOOD PRESSURE WITH OBESE AND NON OBESE PATIENTS  
There was a significant increase in the obese patients with increase in SBP 
and DBP compared with non obese patients.  
 
A several Studies have shown that the relationship between BMI and 
systolic and diastolic blood pressure is nearly linear. In a heart study of 
Framingham provide results in excess weight gain in primary hypertension is 78% 
in men and 65% in women. Several studies indicates excessive weight gain raise 
to BP, but not all obese person are hypertensive. Thus some obese people will 
have less than 140/90mm Hg BP this level indicates hypertension92. 
 
LIPID PROFILE IN OBESE AND NON OBESE  
 Obesity mainly refers to excess of body fat. In the present study of lipid 
profile compared and observed between obese and non obese patients.  Lipid 
profile value of total cholesterol, Triglycerides, LDL,VLDL and HDL levels were 
significantly difference in obese patients compared with non obese patients (G. 
Yuan J Wand., 2006)93, 94. 
 
 Gunnel Ds et al.,199895 observed and reported in obese patients have 
number of metabolic abnormalities in lipid, glycemia, insulin and blood pressure. 
In this present study indicated hyperlipidaemia and hypercholesterolaemia that 
occur in obesity , which associated with increased incidence of coronary heart 
disease and strokes .  
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Haarbo et al96., found positive associations between central fat and total 
cholesterol, triglycerides levels and LDL cholesterol in women especially after 50 
years of age, and a negative association with HDL cholesterol in postmenopausal 
women.  
 
Walton et al  done a study among healthy men between 21 to 77 years of 
age and found a relationship of increasing android fat distribution and elevated 
serum triglycerides and decreased HDL C2 concentrations. But they did not report 
an association between fat distribution with either LDL or HDL cholesterol.  
 
 Reinehr et al. observed cardiac risk factors including higher triglyceride 
(TG) and low density lipoprotei (LDL) and lower high density lipoprotein (HDL) 
in obese children compared to children with normal weight. Roger et al., 
evaluated families who referred to family-oriented clinics to control cardiac risk 
factors. 
 
 Biochemical mechanisms responsible for the association between obesity 
have not been completely elucidated. The triglyceride levels are increases  the 
storage  is associated with a linear, increase in the production of cholesterol,  
which in turn is associated with increased cholesterol secretion in bile and an 
increased risk of gallstone formation and the development of gall bladder 
diseases.  
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 Similarly, increased levels of circulating triacylglycerol in obesity are 
associated with decreased concentrations of high-density lipoprotein, which may 
account for the increased risks for cardiovascular disease and heart attack in obese 
patients (Benhizia., 1997)97. 
 
RENAL PROFILE IN OBESE AND NON OBESE LEVELS 
Overweight and obesity is a one of the risk factors for the development of 
renal function loss. Several studies observed an association between obesity and 
progressive renal damage in subjects with renal disease , in renal transplant 
recipients   and even in the general population (Lamia R et al., 2013) 98, 99.  
 
Obesity subjects have an increased risk of developing hypertension, 
dyslipidaemia, insulin resistance/diabetes mellitus and cardiovascular 
complications, all of which promote chronic kidney disease (CKD)( Saha et al., 
1993)100. 
 
However, even in the absence of these risks, obesity itself is associated 
with the development of CKD and accelerates its progression .  Obesity and/or a 
central body fat distribution are associated with an unfavourable renal 
haemodynamic profile, which may play a role in the susceptibility and 
progression of chronic renal damage (John et al., 2008)101. 
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In human, renal function measured by using indirectly and mainly in urea 
and creatinine in serum. In the present study clearly explains in obese patient’s 
serum urea and Creatinine levels were significantly increased when compared 
with non obese patients.  
 
THYROID PROFILE IN OBESE AND NON OBESE PATIENTS 
Thyroid hormones are responsible for basal metabolism and thermo 
genesis. The body metabolism is mainly depends on protein levels, lipid levels, 
glucose levels and metabolism, food intake and fat oxidation(Becker et al., 
1983)102. 
 
Hypothyroidism, the low levels of thyroid hormones causes increased 
weight and decrease the basal metabolism and thermo genesis. “There is an 
inverse correlation between free thyroxin (FT4) values and body mass index 
(BMI), even when FT4 values remain in the normal range (Racadot., 1991)103, 104. 
 
Always abnormalities in thyroid function may be secondary to weight 
excess”. thyroid hormone and thyroid stimulating hormone (TSH) concentrations 
have been described as normal, elevated or reduced.  
 
Matzen LE et al., 1989105,106  observed the high conversion rate of T4 to T3 
in obese patients has been also interpreted as a defence mechanism, capable of 
counteracting the accumulation of fat be increasing the energy expenditure, based 
metabolic rate. 
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Abnormalities in lipid levels and thyroid hormone in obesity patients 
increases the risk of cardiovascular disease regular monitoring of total cholesterol 
and thyroid hormone levels are mandatory in obese patients. In the present study 
explained thyroid hormone levels were significantly decreased in non obese 
patients107- 110.   
 
LDL ApoB GENE POLYMORPHISM  
In the present study observed the genotypic and allelic frequencies of LDL 
receptor Apo B gene polymorphisms on obese and non obese patients, it shows 
that there was significance difference in the genotype and allele frequencies of 
LDL Apo B polymorphism between obese and non obese patients.  
 
S.H. Lye et al., 2013111, 112 have reported ethnic differences in risk and 
prevalence of metabolic diseases including obesity. This may be related to 
patterns of ethnic-specific body fat distribution. Dyslipidemias, a group of 
biochemical disorders, is frequently encountered in obese individuals. The 
important characters of dyslipidemia is increased level of triglycerides , high 
levels of free fatty acids, .(atherogenic) low density lipoprotein cholesterol (LDL-
C) particles and raised apolipoprotein B (Apo B) values.  
 
However, there is a considerable heterogeneity of plasma lipid profile 
among obese people. The precise cause of this heterogenecity is not entirely clear 
but has been partly attributed to the degree of visceral adiposity (Ashavaid et al., 
2000)112- 114. 
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S.E.A. Leigh et al., 2008115, 116  also reported that significant difference in 
allelic frequencies of LDL receptor Apo B gene polymorphism. LDL receptor 
Apo B polymorphism does not leads to changes in the amino acid sequence and 
cannot be implicated at structure level. It is possible that some polymorphism 
might be present.  
 
Saha et al  showed a strong disequilibrium between insertion/deletion 
polymorphism and the LDL receptor Apo B gene. 
 
 E. Langenhoven117- 119 all in 2007 studied the apolipoprotein B gene 
polymorphism in patients with essential hypertensive and related obesity 
compared with healthy controls in northern Chinese population. 
 
In the present study clearly observed that there was no evidence associated 
LDL receptor Apo B gene polymorphism with obesity and lipid profile. 
 
 
  
Summary 
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SUMMARY 
 
o Metabolic syndrome is also known as metabolic syndrome X, cardio 
metabolic syndrome, syndrome X, insulin resistance syndrome, Reaven's 
syndrome.  
o The prevalence of LDL receptor Apo B gene polymorphism   was studied 
in two groups based on obesity and non obesity patients with coronary 
heart disease patients. Out of 100 patients including 50 is obesity patients 
and 50 were non obese patients.  
o BMI were significantly increased in obese patients when compared with 
non obese coronary heart disease patients.  
o Urea and creatinine levels were significantly increased in obese patients 
when compared with non obese patients. 
o The blood levels of random glucose were estimated in two groups of 
coronary heart disease patients. The random glucose levels were 
significantly elevated in obese patients when compared with non obese 
coronary heart disease patients.  
o Obesity is probably the most important modifiable acquired risk factor in 
the pathogenesis of types 2 diabetes. 
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o Blood pressure levels were significantly increased in obese patients. 
o If obesity to increase in adiposity characterized by decreased HDL-C and 
increased triglycerides levels in body. 
o LDL Receptor Apo B gene polymorphism gene alleles and genotype were 
significantly difference in obese and non obese coronary heart disease 
patients.  
o LDL Receptor ApoB gene polymorphism is a one of the marker to 
differentiate Obese and non obese coronary heart disease patients.  
 
Conclusion 
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CONCLUSION 
 
 Obesity increase the risk of several serious chronic diseases, such as type 2 
diabetes, cardiovascular disease, hypertension and stroke, 
hypercholesterolemia, hypertriglyceridemia, arthritis, asthma and certain 
forms of cancer.  
 In our study 20% of the study population have LDL receptor Apo B gene 
polymorphism with coronary heart disease. 
 The present study has some clinical significance that, LDL receptor Apo B 
gene polymorphism and lipid profile levels are very important marker for 
obese with coronary heart disease patients.  
 The study has scientific importance since it is directed at the health concern 
of the young generation. 
 
Limitations of the study 
  
86 
 
 
LIMITATIONS OF THE STUDY 
 
 The limitation of this study is its cross-sectional nature. The cross sectional 
design of the study also means that the data was collected at one point of 
time, so causal relationship cannot be ascertained and there is a high 
potential for confounding.  
 Despite these weaknesses, the cross sectional design was observed to be 
the most appropriate design due its ability to establish associations, low 
participant burden and usefulness within limited timeframes and budget of 
the study.  
 
 
 
 
 
 
 
 
 
 
 
 
Scope for further studies 
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FUTURE SCOPE 
 
 The study has significance since it is done in obese and non obese 
coronary heart disease patients it is directed towards the health of the 
young generation. 
 The study can be extended with the other markers.  
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High Density Lipoprotein 
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International Units 
Indian Council Of Medical Research 
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Low Density Lipoprotein 
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Milligrams/decilitre 
Mill moles/litre 
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MAPK 
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ng/ml 
nmol/L 
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NPY 
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POD 
PTH 
PTHrP 
PYY3-36 
STAT 
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Parathyroid hormone 
Parathyroid hormone related protein 
Peptide YY3-36 consisting of 36 amino acids 
Signal Transducer and Activation of Transcription 
Standard Deviation 
Total Cholesterol 
Triglycerides 
Tetrahydrocannibol 
UltraViolet 
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World Health Organisation 
 
 INFORMATION SHEET 
 Your blood sample has been accepted. 
 We are conducting a study on apparently healthy individuals attending Karpaga 
Vinayaga Institute of Medical Sciences,Kanchipuram Distric-603308 and for 
that your blood sample may be valuable to us. 
 The purpose of this study is to identify Detection and comparison of LDL 
receptor gene Apo B polymorphism in obese patients and non obese 
patients with suspected coronary heart disease with the help of certain 
special tests. 
 We are selecting certain cases and if your blood sample is found eligible, we 
may be using your blood sample to perform extra tests and special studies 
which in any way do not affect your final report or management. 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
    Signature of participant                                  Signature of investigator       
 PATIENT CONSENT FORM 
Title of the study : Detection and comparison of LDL receptor gene Apo B 
polymorphism in obese patients and non obese patients with suspected coronary 
heart disease. 
Name :        Date  : 
 
Age :        OP No : 
 
Sex :                 Individual ID  : 
The details of the study have been provided to me in writing and explained to 
me in my own language. 
I confirm that I have understood the above study and had the opportunity to ask 
questions. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. 
I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). 
I have been given an information sheet giving details of the study. 
I fully consent to participate in the above study.   
         
    Signature of participant                                  Signature of investigator                                                                          
 PROFORMA FOR PATIENT DETAILS 
 
NAME: 
AGE: 
GENDER: 
OP.NO.: 
INDIVIDUAL ID. NO: 
ADDRESS: 
HISTORY: 
GENERAL EXAMINATION: 
HEIGHT: 
WEIGHT: 
BLOOD PRESSURE:                                   PULSE: 
SYSTEMIC EXAMINATION: 
CARDIOVASCULAR SYSTEM: 
RESPIRATORY SYSTEM: 
ABDOMEN: 
NERVOUS SYSTEM: 
INVESTIGATION: 
DIAGNOSIS: 
 
 
 MASTER CHART 
S.no Age Sex BMI RBS FBS PP T.CHO TGL HDL LDL VLDL Urea creatinine BP T3 T4 TSH HB 
1 49 M 26 270   233 260 26 189 57 77 2 110/80 11 5 5 13 
2 49 M 30 110   289 320 52 198 62 31 0.9 90/72 16 6 4 12.4 
3 51 M 19.8 105   153 254 89 142 30.6 25 0.8 100/70 39 9 13 12 
4 55 M 20 100   165 67 35 54 7.2 24 0.9 100/70 14 8 4.4 11.9 
5 53 F 25.2  73 130 265 300 76 231 60 26 0.6 120/80 23 6 3 13 
6 29 M 21.7 99   157 78 34 187.85 15 27 0.5 110/70 23 8 3.4 13 
7 32 F 19.4  97 138 220 211 87 189 42.2 31 0.9 120/82 12 7 6 14.2 
8 25 M 21 83   220 234 29 160 46.8 21 0.8 160/90 37 17 7.56 12.9 
9 40 M 29 140   240 190 41.1 134 38 33 0.7 110/80 17 9 4.2 13 
10 55 M 16.5 105   150 91 41 47.8 18.2 34 0.8 90/72 19 11 2.9 14.1 
11 50 M 15.4 80   156 101 57.4 78 20.2 26 0.9 110/80 12 8 3.1 12 
12 38 F 21 163   290 300 23 167 60 32 0.6 150/100 15 8 3.4 12 
13 22 F 14.6 154   230 200 23 189 40 34 0.5 110/70 14 6 4.2 12 
14 42 M 20 102   178 143 47.7 189 28 25 0.9 110/70 18 8 3 10.5 
15 45 M 19 110   220 90 12 176 18 24 0.7 110/80 12 9 4.3 14.2 
16 55 F 27.3 110   231 123 12 378 24.6 26 0.8 150/100 35 7 3.8 12.6 
17 40 M 23  110 138 150 189 52 178 37 56 1.9 110/80 59 2.9 4.2 12 
18 50 F 17.4 110   245 259 79 167 51.8 24 0.6 150/100 13 9 4.1 14.2 
19 41 M 29 101   230 200 21 136 40 21 0.7 110/70 56 2.1 4.3 13.2 
20 39 F 20 90   176 350 50 57 70 27 0.8 90/70 14 8 5 6.4 
21 40 M 26  98 123 234 189 28 46.8 37 35 0.9 110/70 20 8 4 14 
22 52 M 21.4 110   150 92 53.9 168 11.4 56 0.5 110/80 21 7 4.2 12 
23 53 F 25.4  98 139 276 251 21 245 50.2 27 6 110/80 13 8 9 12 
24 49 F 21 90   209 300 29 123 60 29 0.7 110/70 11 6 4.6 15 
 25 35 F 16 85   175 99 39.5 115.7 19.8 28 0.9 110/80 21 10 3.1 12 
26 32 M 27 109   289 254 26 180 50.8 28 0.7 120/80 23 7 2.4 12.9 
27 55 M 18 74   167 280 53 45 56 23 0.8 90/70 19 8 3.6 13.2 
28 50 M 21  102 128 278 220 67 113.6 44 12 0.9 100/70 22 6 4.4 13.7 
29 28 M 16.2 110   159 234 21 72.2 46.8 32 0.7 130/90 39 18 12.6 13 
30 49 M 26 110   189 141 88 107 28.2 56 3.1 160/100 12 9 2.3 12 
31 51 M 21 167   158 137 23 82.4 27.4 26 0.8 120/80 18 7 2.6 14.2 
32 42 M 21 72   234 190 29 66.5 38 21 0.5 110/80 16 8 4.2 13.9 
33 45 F 25 180   160 278 30 89 55.6 27 0.7 100/70 29 6 3.4 12 
34 55 F 28.8 110   321 120 23 77.9 24 23 0.9 90/70 16 7 3.1 12.6 
35 39 F 27 109   341 89 25 92.7 17.4 34 0.9 110/70 17 8 2.4 12.3 
36 33 F 31  88 121 241 300 67 189 60 23 0.8 120/80 17 6 4.2 8.9 
37 50 M 22 77   200 99 54 180 49 22 0.7 120/70 14 7 3.2 13.5 
38 39 F 31.2 86   289 210 30 177 42 45 1.7 110/70 12 9 2.1 14.5 
39 48 M 26.4 77   300 220 45 231 44 25 0.7 120/80 17 8 3.2 12 
40 51 M 21 96   187 125 82 78 147 24 0.8 100/70 34 6 2.5 13.2 
41 38 F 19 102   234 321 24 178 64.2 26 0.9 110/80 38 7 15 13 
42 39 M 28 88   320 178 54 120 34 28 0.8 100/70 17 11 4.2 13.4 
43 29 M 23 98   290 200 23 19.2 40 26 0.7 110/80 14 21 3.5 12 
44 50 F 20 98   290 342 43 123 68.4 25 0.8 120/80 29 21 5.3 13.2 
45 39 F 32 100   150 239 26 189 47.8 28 0.9 120/80 14 7 3.2 12.6 
46 43 F 31.3 177   300 290 27 167 58 24 0.3 110/80 16 9 2.4 15 
47 49 F 17.3 98   267 200 26 100 40 23 0.4 130/80 21 7 2.1 6.9 
48 50 F 20 201   178 98 55.2 56 19.6 34 0.5 180/90 34 10 4.2 14.2 
49 45 F 28 97   290 276 45 193 55.2 36 0.6 110/90 12 9 3.1 12 
50 45 M 21 176   150 123 19 200 24 31 0.7 150/90 12 9 3.21 12.5 
 51 50 F 20.3 110   167 98 26 189 19.6 28 0.5 110/70 17 21 3.4 12 
52 50 F 20.4 111   165 98 45 85.8 19.6 27 0.6 100/70 16 11 4.1 12 
53 50 F 22 96   165 89 40 189 17.8 55 0.7 100/70 23 7 5 12 
54 50 F 22 106   156 78 36 178 15.6 45 2.1 130/90 14 11 3.2 13.7 
55 55 F 29 90   173 110 21 67.9 22 34 0.5 110/70 13 7 3.5 12.9 
56 38 M 22.6 98   156 52 52 28 10.4 29 3.4 100/60 14 8 4.3 11.6 
57 32 M 27.4 85   200 145 23 134 29 18 0.5 120/90 21 21 1.7 13.3 
58 34 F 19 110   183 132 54 134 26.4 24 0.5 110/60 16 9 4.5 12.4 
59 40 F 28  111 105 231 121 15 70 24.2 25 0.6 120/80 21 8 3.23 12 
60 30 M 23 90   230 90 45 78 18 28 0.7 140/80 16 8 5 12 
61 41 M 26.2 88   167 123 42 43 24 28 0.6 150/90 14 9 4.2 7.9 
62 26 F 28 76   290 220 26 190 44 45 2.8 160/100 13 9 3.3 10 
63 55 F 29 100   160 102 23 49.8 20.4 32 1.9 110/70 15 8 3.2 12.9 
64 48 M 29 180   156 240 19 234 48 25 0.5 120/90 18 9 2.3 13 
65 53 F 26.7 110   290 267 30 102.4 53.4 29 0.7 120/80 11 8 4.3 12 
66 50 M 24 102   178 89 34 190 17.8 28 0.8 130/90 21 9 3.5 12.8 
67 30 M 26.9 89   230 200 76 167 40 21 0.8 170/100 15 7 5 7 
68 42 F 27 81   287 249 12 68.6 49.8 30 0.9 120/90 12 12 5 11.9 
69 53 M 21 98   265 267 45 231 53.6 27 0.7 120/90 23 6 3.2 12.2 
70 43 F 30  155 247 183 300 24 190 60 29 0.6 150/100 15 8 3.2 12 
71 49 M 26.9 200   256 134 45 190 31.8 30 0.5 150/100 23 7 2.62 11 
72 35 F 21  70 96 150 100 45 150 20 23 0.6 120/80 14 6 3.2 9.1 
73 47 M 28.3 112   278 200 23 56 40 30 0.7 150/100 12 9 1.89 5 
74 38 F 29  117 134 211 134 39 178 26 25 0.8 120/90 21 6 2.65 5.9 
75 52 M 23 109   264 189 23 83.2 19.2 28 0.9 120/90 23 9 3 14.2 
76 50 F 27 100   208 240 87 190 48 36 0.8 160/100 21 7 3.1 6.9 
 77 34 F 21 98   287 152 89 200 30.4 32 1.9 120/70 43 8 13.6 13.4 
78 30 F 25.2 110   230 280 44 198 56 39 0.6 120/90 14 6 3.1 6.4 
79 50 F 25 300   278 231 89 162 46.2 25 0.7 110/70 39 8 2.1 11.9 
80 28 M 20.9 82   150 92 36 84.6 18.4 32 0.9 120/90 14 11 2.4 5.8 
81 53 M 21  83 107 167 89 89 89 23 36 1.6 150/100 21 12 2.1 15.3 
82 48 M 29.4  116 153 300 123 56 178 43.2 26 0.7 120/90 23 8 2.9 6.9 
83 32 M 28 89   210 143 43 81 54 29 1.8 150/90 38 9 4.2 15.8 
84 35 F 19  110 123 179 290 50 108.2 58 26 0.6 110/72 12 7 3.4 7 
85 48 M 26.3 170   245 280 67 108.2 56 26 0.6 160/90 34 8 3.4 12 
86 40 M 23.1 74   183 75 100 117 15 28 0.8 110/90 21 7 4.1 12 
87 28 M 21.3 100   156 73 43 92.4 14.6 35 0.7 110/60 23 9 1.1 6.6 
88 32 F 29 81   300 234 21 179 46 28 0.9 100/60 37 9 3.1 7.9 
89 36 M 27.3 109   321 167 23 180 33 49 2.1 150/90 12 6 2.3 5.5 
90 45 M 22.6 110   260 89 44 129.2 17.8 31 0.8 150/100 21 7 3.1 6.7 
91 42 M 21.6 109   278 180 21 38.5 36 27 0.7 120/90 21 8 1.1 16.4 
92 32 M 28.1 99   150 132 29 30.4 38.6 30 0.6 100/70 21 0.6 3.1 5.7 
93 55 F 29 109   156 89 54 14.2 17.8 40 0.9 100/80 12 19 2.1 13 
94 55 F 29.8  150 310 150 78 21 156 15.6 26 0.5 150/100 24 8 2.1 13.6 
95 36 M 27.2 106   210 180 29 190 36 27 0.5 120/80 16 6 8.4 12 
96 55 F 32.9 110   150 71 43 167 14.2 80 2.4 120/70 17 9 3.1 13.8 
97 38 F 22 108   211 290 46 190 58 45 2.1 120/90 21 9 3.1 12 
98 55 F 33.5 100   150 56 29 123 11.2 20 0.9 110/60 18 10 4.34 14 
99 53 F 27 204   268 289 12 82 57.8 40 0.7 110/70 19 11 3.23 12 
100 52 F 25.2  101 134 262 234 89 231 46.8 30 0.7 170/100 36 9 2.36 11.7 
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